PDF(Pubmed)
Abstract：
UNASSIGNED: The predictive value of programmed death-ligand 1 (PD-L1) expression in nasopharyngeal cancer (NPC) patients receiving immune checkpoint inhibitors (ICIs) remains controversial. This study aimed to evaluate the optimal threshold of PD-L1 expression in predicting the efficacy of ICIs in patients with recurrent or metastatic (R/M) NPC.
UNASSIGNED: A meta-analysis was performed by retrieving relevant literature from PubMed, EMBASE, and Cochrane Library databases. Data on the pooled risk ratio (RR), mean overall survival (OS), progression-free survival (PFS), overall response rate (ORR) with 95% confidence interval, and 1%, 10%, and 25% PD-L1 expression cutoff points were obtained to examine the role of PD-L1 as a biomarker in R/M NPC patients receiving immunotherapy.
UNASSIGNED: In total, 1,312 patients from 14 studies were included. An improvement in PFS was observed in both patients with PD-L1 ≥ 1% (RR = 0.76, 95% CI 0.62-0.92, P = 0.005) and those with PD-L1 < 1% (RR = 0.68, 95% CI: 0.35-1.32, P = 0.26) who received first-line treatment with immunotherapy, with no significant difference between these subgroups. The pooled ORR was significantly higher in patients with PD-L1 ≥ 1% (ORR = 0.37) than in those with PD-L1 < 1% (ORR = 0.22) (P < 0.01) undergoing subsequent-line treatment. However, when we used the PD-L1 cutoff values of 10% and 25%, there was no significant difference between the positive (PD-L1 expression ≥ the cutoff value) and negative (PD-L1 expression < the cutoff value) subgroups. PD-L1 ≥ 1% also tended to be associated with better PFS and OS.
UNASSIGNED: Our meta-analysis suggested that first-line immunotherapy could significantly improve PFS in R/M NPC patients, regardless of the PD-L1 expression levels. Positive PD-L1 expression (≥ 1%) might be a potential predictive biomarker for a better overall response to immunotherapy in R/M NPC patients in subsequent-line setting.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024495841 PROSPERO, identifier CRD42024495841.
UNASSIGNED: A meta-analysis was performed by retrieving relevant literature from PubMed, EMBASE, and Cochrane Library databases. Data on the pooled risk ratio (RR), mean overall survival (OS), progression-free survival (PFS), overall response rate (ORR) with 95% confidence interval, and 1%, 10%, and 25% PD-L1 expression cutoff points were obtained to examine the role of PD-L1 as a biomarker in R/M NPC patients receiving immunotherapy.
UNASSIGNED: In total, 1,312 patients from 14 studies were included. An improvement in PFS was observed in both patients with PD-L1 ≥ 1% (RR = 0.76, 95% CI 0.62-0.92, P = 0.005) and those with PD-L1 < 1% (RR = 0.68, 95% CI: 0.35-1.32, P = 0.26) who received first-line treatment with immunotherapy, with no significant difference between these subgroups. The pooled ORR was significantly higher in patients with PD-L1 ≥ 1% (ORR = 0.37) than in those with PD-L1 < 1% (ORR = 0.22) (P < 0.01) undergoing subsequent-line treatment. However, when we used the PD-L1 cutoff values of 10% and 25%, there was no significant difference between the positive (PD-L1 expression ≥ the cutoff value) and negative (PD-L1 expression < the cutoff value) subgroups. PD-L1 ≥ 1% also tended to be associated with better PFS and OS.
UNASSIGNED: Our meta-analysis suggested that first-line immunotherapy could significantly improve PFS in R/M NPC patients, regardless of the PD-L1 expression levels. Positive PD-L1 expression (≥ 1%) might be a potential predictive biomarker for a better overall response to immunotherapy in R/M NPC patients in subsequent-line setting.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024495841 PROSPERO, identifier CRD42024495841.
摘要：
■接受免疫检查点抑制剂（ICIs）的鼻咽癌（NPC）患者中程序性死亡配体1（PD-L1）表达的预测价值仍存在争议。这项研究旨在评估PD-L1表达的最佳阈值，以预测ICIs在复发性或转移性（R/M）NPC患者中的疗效。
■通过从PubMed检索相关文献进行荟萃分析，EMBASE,和Cochrane图书馆数据库。关于合并风险比率(RR)的数据，平均总生存期（OS），无进展生存期（PFS），总有效率(ORR)，95%置信区间，1%,10%,并获得25%PD-L1表达的截止点,以检查PD-L1作为接受免疫治疗的R/MNPC患者的生物标志物的作用.
■总共，包括来自14项研究的1,312名患者。在PD-L1≥1％（RR=0.76，95％CI0.62-0.92，P=0.005）和PD-L1<1％（RR=0.68，95％CI：0.35-1.32，P=0.26）的患者中，均观察到PFS的改善。这些亚组之间没有显着差异。PD-L1≥1％（ORR=0.37）的患者合并ORR明显高于PD-L1<1％（ORR=0.22）（P<0.01）。然而,当我们使用10%和25%的PD-L1截止值时，阳性(PD-L1表达≥临界值)和阴性(PD-L1表达<临界值)亚组之间无显著差异.PD-L1≥1%也倾向于与更好的PFS和OS相关。
■我们的荟萃分析表明，一线免疫疗法可以显着改善R/MNPC患者的PFS，无论PD-L1表达水平如何。PD-L1阳性表达（≥1％）可能是一个潜在的预测生物标志物，用于在随后的线设置中R/MNPC患者对免疫疗法的更好的总体反应。
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD42024495841PROSPERO,标识符CRD42024495841。
■通过从PubMed检索相关文献进行荟萃分析，EMBASE,和Cochrane图书馆数据库。关于合并风险比率(RR)的数据，平均总生存期（OS），无进展生存期（PFS），总有效率(ORR)，95%置信区间，1%,10%,并获得25%PD-L1表达的截止点,以检查PD-L1作为接受免疫治疗的R/MNPC患者的生物标志物的作用.
■总共，包括来自14项研究的1,312名患者。在PD-L1≥1％（RR=0.76，95％CI0.62-0.92，P=0.005）和PD-L1<1％（RR=0.68，95％CI：0.35-1.32，P=0.26）的患者中，均观察到PFS的改善。这些亚组之间没有显着差异。PD-L1≥1％（ORR=0.37）的患者合并ORR明显高于PD-L1<1％（ORR=0.22）（P<0.01）。然而,当我们使用10%和25%的PD-L1截止值时，阳性(PD-L1表达≥临界值)和阴性(PD-L1表达<临界值)亚组之间无显著差异.PD-L1≥1%也倾向于与更好的PFS和OS相关。
■我们的荟萃分析表明，一线免疫疗法可以显着改善R/MNPC患者的PFS，无论PD-L1表达水平如何。PD-L1阳性表达（≥1％）可能是一个潜在的预测生物标志物，用于在随后的线设置中R/MNPC患者对免疫疗法的更好的总体反应。
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD42024495841PROSPERO,标识符CRD42024495841。
